## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.0% below STRENGTH zone (3.0-6.0%); PEG 1.35 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($305.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Axa S.A. Sells 155,294 Shares of UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251209T083459 | Neutral | Relevance: 100%
-  Axa S.A. has reduced its stake in UnitedHealth Group by 34.6%, selling 155,294 shares and now holding 293,176 shares valued at $91.46 million. Despite this, institutional ownership remains high at 87.86%, with other major investors like Norges Bank and Dodge & Cox significantly increasing their positions. UnitedHealth Group reported strong Q3 earnings, beating EPS estimates, and announced a quarterly dividend of $2.21, reflecting a 2.7% yield.

**2. SVB Wealth LLC Sells 4,770 Shares of UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251208T122946 | Neutral | Relevance: 99%
- SVB Wealth LLC has reduced its stake in UnitedHealth Group Incorporated (NYSE:UNH) by selling 4,770 shares, bringing its total holdings to 17,725 shares valued at $5.53 million. This comes as UnitedHealth beat EPS estimates with $2.92 and reported $113.16 billion in revenue, also announcing a quarterly dividend of $2.21. The stock, largely institutionally held, has a mixed analyst consensus of "Hold" with an average target price of $385.54.

**3. State Street Corp Decreases Stock Position in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251209T131200 | Somewhat-Bullish | Relevance: 99%
-  State Street Corp reduced its stake in UnitedHealth Group Incorporated (NYSE:UNH) by 0.9% in the second quarter, selling 411,970 shares and now owning 44,926,544 shares valued at $14.02 billion. Despite this decrease, UnitedHealth Group remains State Street Corp's 29th largest holding, comprising approximately 0.5% of its portfolio. Other institutional investors, such as Brighton Jones LLC and Revolve Wealth Partners LLC, significantly increased their positions in UNH during the same period.

**4. Daiwa Securities Group Inc. Increases Stock Position in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251209T103146 | Somewhat-Bullish | Relevance: 98%
-  Daiwa Securities Group Inc. increased its stake in UnitedHealth Group Incorporated (NYSE:UNH) by 2.2% in Q2 2025, bringing its total holdings to 223,981 shares valued at $69.88 million. The article details other institutional investments, UnitedHealth Group's financial performance, recent dividend announcements, and current analyst ratings, with the stock holding an average "Hold" rating and a consensus target price of $385.54.

**5. UnitedHealth Group Incorporated $UNH Shares Purchased by London & Capital Asset Management Ltd**
- Source: MarketBeat | 20251209T131807 | Somewhat-Bullish | Relevance: 98%
-  London & Capital Asset Management Ltd significantly increased its stake in UnitedHealth Group Incorporated (NYSE:UNH), boosting its shares by 35.6% in the second quarter to own 118,494 shares valued at $36,961,000. Several other institutional investors also adjusted their holdings, with UnitedHealth Group remaining a significant part of many portfolios. Analysts have issued varied ratings, with a consensus "Hold" rating and an average target price of $385.54, while the company recently announced a quarterly dividend of $2.21 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 23 ($0.00M) |
| Sells | 1 ($0.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 10.2% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.35 suggests fair value with growth premium. Forward P/E 18.3x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $293.1B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.35 |
| Forward P/E | 18.3 |
| Current P/E | 19.8 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.2% to -2.0% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.0pp (needs >3.0% for momentum thesis). Below SMA200 (0.90x), long-term trend not supportive. MACD histogram positive (1.25), confirming momentum. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.05% (CS: 35) | Weak |
| RSI_14 | 45.2 | Neutral |
| MACD Histogram | 1.25 | Bullish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 0.948x | Below |
| vs SMA200 | 0.898x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $323.60
- **Stop Loss:** $305.56 (5.6% risk)
- **Target:** $341.64 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 16
- **Position Value:** $5,177.60
- **Portfolio %:** 5.18%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*